Show simple item record

dc.contributor.authorGleeson, M
dc.contributor.authorPeckitt, C
dc.contributor.authorCunningham, D
dc.contributor.authorGibb, A
dc.contributor.authorHawkes, EA
dc.contributor.authorBack, M
dc.contributor.authorYasar, B
dc.contributor.authorFoley, K
dc.contributor.authorLee, R
dc.contributor.authorDash, J
dc.contributor.authorJohnson, H
dc.contributor.authorO'Hara, C
dc.contributor.authorWotherspoon, A
dc.contributor.authorAttygalle, A
dc.contributor.authorMenasce, L
dc.contributor.authorShenjere, P
dc.contributor.authorPotter, M
dc.contributor.authorEthell, ME
dc.contributor.authorDearden, C
dc.contributor.authorRadford, J
dc.contributor.authorChau, I
dc.contributor.authorLinton, K
dc.date.accessioned2017-11-22T16:05:08Z
dc.date.issued2018-07
dc.identifier.citationLeukemia & lymphoma, 2018, 59 (7), pp. 1586 - 1595
dc.identifier.issn1042-8194
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/933
dc.identifier.eissn1029-2403
dc.identifier.doi10.1080/10428194.2017.1393671
dc.description.abstractWe evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI) ≥ 2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p = .001) and OS (p = .046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
dc.formatPrint-Electronic
dc.format.extent1586 - 1595
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
dc.subjectHumans
dc.subjectLymphoma, T-Cell, Peripheral
dc.subjectNeoplasm Metastasis
dc.subjectRecurrence
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectNeoplasm Staging
dc.subjectPrognosis
dc.subjectTreatment Outcome
dc.subjectCombined Modality Therapy
dc.subjectHematopoietic Stem Cell Transplantation
dc.subjectSurvival Analysis
dc.subjectFollow-Up Studies
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectMiddle Aged
dc.subjectFemale
dc.subjectMale
dc.subjectYoung Adult
dc.subjectConsolidation Chemotherapy
dc.subjectInduction Chemotherapy
dc.subjectBiomarkers
dc.subjectUnited Kingdom
dc.titleOutcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital.
dc.typeJournal Article
rioxxterms.funderThe Institute of Cancer Research
rioxxterms.identifier.projectUnspecified
rioxxterms.versionofrecord10.1080/10428194.2017.1393671
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/under-embargo-all-rights-reserved
rioxxterms.licenseref.startdate2018-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfLeukemia & lymphoma
pubs.issue7
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume59
pubs.embargo.termsNot known
icr.researchteamMedicine (RMH Smith Cunningham)en_US
dc.contributor.icrauthorCunningham, Daviden
dc.contributor.icrauthorChau, Ianen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record